A practical overview of the key provisions of India's NDCT Rules, 2019 — approval timelines, ethics committee registration and participant compensation.
The New Drugs and Clinical Trials Rules, 2019 (NDCT Rules) brought India's clinical research framework under a single, comprehensive set of rules. For sponsors planning studies in India, understanding these provisions early helps avoid delays later.
Defined review timelines
The rules introduced defined timelines for the review of clinical trial applications by the Central Licensing Authority. Applications for drugs discovered and developed in India benefit from shorter timelines than other applications, making early planning of the regulatory strategy important.
Ethics committee registration
Ethics committees reviewing clinical trials must be registered with the Central Licensing Authority. Sponsors should confirm the registration status of each site's ethics committee during feasibility.
Compensation and medical management
The rules set out obligations for free medical management and compensation in case of trial-related injury or death. Budgets and insurance arrangements should reflect these obligations from the outset.
Local clinical trial waivers
In certain circumstances, the requirement for a local clinical trial may be waived for drugs already approved in specified countries. Each case is assessed individually by the regulator.
What this means in practice
- Plan regulatory and ethics submissions in parallel wherever possible.
- Verify ethics committee registration during site selection.
- Build compensation and insurance requirements into budgets early.
- Keep complete, inspection-ready documentation from day one.
This article is a general overview and does not constitute legal or regulatory advice. Always refer to the current text of the rules and official CDSCO guidance.